Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
January 03, 2025 | 00:43
Hanx Biopharmaceuticals, CO. Ltd, today announced the first patient dosing in Australia on Dec 30, 2024 for Phase 1 clinical trial of HX044 in patients with advanced solid tumors.
Mobile Version